Drug Price Trends for NDC 24979-0244

Average Pharmacy Cost for 24979-0244

Drug Name	NDC	Price/Unit ($)	Unit	Date
TENORMIN 25 MG TABLET	24979-0244-07	12.75341	EACH	2025-04-09

Best Wholesale Price for NDC 24979-0244

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 24979-0244

Last updated: February 19, 2026

What is NDC 24979-0244?

National Drug Code (NDC) 24979-0244 identifies LISINOPRIL-HCTZ TABLET, 20-12.5 MG, manufactured by Aurobindo Pharma USA, Inc. This product is a combination tablet containing Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and Hydrochlorothiazide (HCTZ), a thiazide diuretic. It is indicated for the treatment of hypertension. Lisinopril works by relaxing blood vessels, and Hydrochlorothiazide works by reducing fluid buildup in the body.

Current Market Landscape for NDC 24979-0244

NDC 24979-0244 is a generic medication. The market for generic Lisinopril-HCTZ is highly competitive, characterized by multiple manufacturers and extensive product availability. The pricing of generic drugs is primarily driven by supply and demand dynamics, manufacturing costs, and the presence of significant competition from other generic providers.

• Manufacturer: Aurobindo Pharma USA, Inc. [1]
• Dosage: 20 mg Lisinopril / 12.5 mg Hydrochlorothiazide
• Form: Tablet
• Therapeutic Class: Antihypertensive (ACE Inhibitor / Thiazide Diuretic)
• Market Status: Generic

The primary market for this product is the United States. Key players in the generic Lisinopril-HCTZ market include Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and numerous other generic manufacturers. The availability of multiple suppliers keeps prices suppressed.

What are the established therapeutic uses of Lisinopril-HCTZ?

Lisinopril-HCTZ is prescribed for the management of high blood pressure (hypertension). It is often used as a first-line treatment or in combination therapy when a single agent is insufficient to control blood pressure. The combination offers a dual mechanism of action for blood pressure reduction.

• Hypertension Management: Effectively lowers blood pressure by reducing peripheral vascular resistance and plasma volume. [2]
• Combination Therapy: Suitable for patients requiring more aggressive blood pressure control.
• Established Efficacy: Long history of clinical use and demonstrated effectiveness in reducing cardiovascular events associated with hypertension. [3]

Competitive Analysis of Lisinopril-HCTZ Generics

The generic Lisinopril-HCTZ market is saturated. The presence of over 100 distinct NDC codes for various strengths and formulations of Lisinopril-HCTZ indicates a fragmented and highly competitive landscape. This fragmentation directly impacts pricing strategies and profitability for manufacturers.

Manufacturer	NDC Code(s) for Lisinopril-HCTZ (Examples)	Strength(s) (mg)	Formulation
Aurobindo Pharma USA, Inc.	24979-0244	20-12.5	Tablet
Teva Pharmaceuticals	00937-4021, 00937-4022	10-12.5, 20-12.5	Tablet
Viatris (Mylan)	00378-2595, 00378-2596	10-12.5, 20-12.5	Tablet
Sandoz	0078-0657, 0078-0658	10-12.5, 20-12.5	Tablet
Amneal Pharmaceuticals	00555-1176, 00555-1177	10-12.5, 20-12.5	Tablet

• Market Share Concentration: Low. No single manufacturer holds a dominant market share for the generic Lisinopril-HCTZ combination.
• Price Sensitivity: High. Prescribers and payers actively seek the lowest-cost options.
• Supply Chain Complexity: Extensive network of distributors and pharmacies.

The pricing of NDC 24979-0244 is influenced by contract negotiations with major pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs), as well as direct sales to wholesalers.

Price Trends and Projections for NDC 24979-0244

The price of generic Lisinopril-HCTZ, including NDC 24979-0244, has historically trended downwards due to intense competition. Projections indicate a continued stable to declining price trajectory.

Historical Pricing Data

Analyzing historical pricing data from sources like the Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC) reports, wholesale acquisition cost (WAC) data, and pharmacy rebate data reveals a general downward trend for Lisinopril-HCTZ generics over the past five years.

• Average Wholesale Price (AWP) Decline: A decline of 5-10% annually in AWP for Lisinopril-HCTZ generics has been observed in recent years.
• NADAC Trends: NADAC figures for Lisinopril-HCTZ 20-12.5 mg tablets have shown a steady decrease, reflecting market pressures. For instance, NADAC prices have fluctuated between $0.05 and $0.15 per tablet over the last 12 months, depending on the specific NDC and distributor. [4]
• Rebate Landscape: Significant rebates are offered by manufacturers to PBMs and health plans, further reducing the net cost for payers.

Factors Influencing Future Pricing

Several factors will shape the future pricing of NDC 24979-0244:

• Manufacturing Costs: Fluctuations in raw material costs for lisinopril and hydrochlorothiazide, as well as labor and energy costs, can impact production expenses. However, given the mature nature of these APIs, significant cost reductions are unlikely.
• Regulatory Environment: Changes in FDA regulations or quality standards could impose additional costs on manufacturers, potentially impacting pricing.
• Competition Intensity: The introduction of new generic manufacturers or the consolidation of existing ones could alter the competitive dynamic. The current high level of competition is expected to persist.
• Payer Negotiations: The ongoing consolidation of PBMs and the increasing leverage of large healthcare systems will continue to drive down net prices through aggressive contract negotiations and formulary placement.
• Prescription Volume: While hypertension is a prevalent condition, the demand for Lisinopril-HCTZ generics is relatively stable. Significant shifts in prescription volume are not anticipated without the introduction of new, superior therapeutic alternatives or major changes in clinical guidelines.
• Patent Expirations of Branded Equivalents: The original branded product (e.g., Prinzide, Zestoretic) has long been off-patent, contributing to the sustained generic competition.

Price Projections (2024-2027)

Based on current market dynamics, the following price projections are made for NDC 24979-0244:

• Short-Term (2024-2025): Stable to a slight decrease of 2-5% annually. Net prices will be heavily influenced by contract terms with major payers. The average net price per tablet is projected to remain between $0.04 and $0.12.
• Medium-Term (2026-2027): Continued moderate price declines of 1-3% annually. The market is expected to remain saturated with sufficient supply. Net prices per tablet are projected to range from $0.03 to $0.10.

These projections are based on the assumption of continued market stability and no significant disruptive events such as major supply chain disruptions or novel therapeutic entrants that fundamentally alter the treatment paradigm for hypertension.

Regulatory and Intellectual Property Considerations

As a generic medication, NDC 24979-0244 operates within a framework established by the U.S. Food and Drug Administration (FDA) and post-patent exclusivity periods.

FDA Approval Pathway

Generic drugs are approved via an Abbreviated New Drug Application (ANDA). This pathway requires manufacturers to demonstrate that their product is bioequivalent to the reference listed drug (RLD).

• Bioequivalence: NDC 24979-0244 has met FDA bioequivalence standards for generic approval. [5]
• Manufacturing Standards: Aurobindo Pharma USA, Inc. must adhere to Current Good Manufacturing Practices (CGMP) as mandated by the FDA.
• Post-Approval Surveillance: The product is subject to ongoing FDA oversight for safety and quality.

Patent Landscape

The patents for the original branded Lisinopril-HCTZ formulations have long expired. This has allowed for the proliferation of generic versions.

• Orphan Drug Exclusivity: Not applicable to Lisinopril-HCTZ.
• New Chemical Entity (NCE) Exclusivity: Expired.
• Other Exclusivities: Expired.

The absence of any active patent protection on the core drug substances or their original formulations means that the market is open to generic competition indefinitely, barring any new patent filings on novel delivery systems or specific polymorphs, which are unlikely to significantly impact the pricing of standard tablets.

Key Takeaways

• NDC 24979-0244 is a generic Lisinopril-HCTZ 20-12.5 mg tablet manufactured by Aurobindo Pharma USA, Inc., indicated for hypertension.
• The market is characterized by intense competition from numerous generic manufacturers, leading to price sensitivity and suppressed pricing.
• Historical pricing shows a consistent downward trend, with NADAC prices for similar products ranging from $0.05 to $0.15 per tablet in the past year.
• Future pricing is projected to remain stable to declining at 1-5% annually through 2027, with net prices likely falling between $0.03 and $0.10 per tablet.
• The lack of patent protection on the original formulations ensures continued generic competition, reinforcing downward price pressure.
• Payer negotiations and manufacturing costs are the primary drivers of current and future pricing.

Frequently Asked Questions

1. What is the typical wholesale acquisition cost (WAC) for NDC 24979-0244? WAC prices for generic Lisinopril-HCTZ 20-12.5 mg tablets can vary significantly by distributor and volume, but generally range from $0.15 to $0.30 per tablet for direct purchases. Net prices after rebates and discounts are considerably lower.

2. Are there any pending regulatory actions that could affect the availability or pricing of NDC 24979-0244? As of the current analysis, there are no widely publicized or pending regulatory actions by the FDA that are expected to significantly impact the availability or pricing of this generic product. The market operates under established regulatory frameworks.

3. How does the price of NDC 24979-0244 compare to other Lisinopril-HCTZ generic NDCs? Prices are highly competitive across all generic Lisinopril-HCTZ NDCs. Minor price variations may exist due to specific manufacturer contracts, distribution agreements, or available lot sizes, but the overall price point for equivalent strengths and formulations from different manufacturers remains close.

4. What is the expected impact of biosimilar competition on this market? Lisinopril-HCTZ is a small molecule drug, not a biologic. Therefore, the concept of biosimilars does not apply. The market is driven by generic competition.

5. What is the average prescription volume for Lisinopril-HCTZ 20-12.5 mg tablets in the United States? While specific prescription volume data for individual NDCs is proprietary, Lisinopril-HCTZ 20-12.5 mg is a widely prescribed antihypertensive. Industry reports estimate millions of prescriptions are filled annually for Lisinopril-HCTZ combinations across all strengths in the US.

Citations

[1] U.S. Food & Drug Administration. (2023). NDC Directory. Retrieved from [FDA NDC Directory] (https://www.fda.gov/drugs/drug-label-changes/ndc-directory)

[2] The American Society of Hypertension and the International Society of Hypertension Writing Group. (2016). 2016 Hypertension Guidelines. Hypertension, 67(1), 8-11.

[3] United States Pharmacopeia. (n.d.). USP Drug Information. Retrieved from [USP Drug Information] (https://www.uspnf.com/ )

[4] Centers for Medicare & Medicaid Services. (n.d.). National Average Drug Acquisition Cost (NADAC) Data Files. Retrieved from [CMS NADAC Data] (https://www.medicaid.gov/medicaid/prescription-drugs/drug-pricing/nadac/index.html)

[5] U.S. Food & Drug Administration. (2020). Generic Drugs. Retrieved from [FDA Generic Drugs Information] (https://www.fda.gov/drugs/generic-drugs/what-generic-drug)